EUROPEAN COMMISSION APPROVES BLINCYTO® IN PHILADELPHIA CHROMOSOME-NEGATIVE CD19-POSITIVE B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA IN THE CONSOLIDATION PHASE

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Amgen-BLINCYTO

More Like This

AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia

PR Newswire associated0

EUROPEAN COMMISSION APPROVES AMGEN'S IMDYLLTRA® FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER

AbbVie Presents New Data at EHA 2026 Congress for VENCLEXTA®/VENCLYXTO® (venetoclax) in First-Line Chronic Lymphocytic Leukemia Highlighting Long-Term Treatment Outcomes for Patients: Nine-Year Results

AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026

Business Wire logo

Takeda Announces U.S. FDA Approval of Supplemental New Drug Application (sNDA) for ICLUSIG® (ponatinib) in Adult Patients with Newly Diagnosed Ph+ ALL

PR Newswire associated0

Zemcelpro® (UM171 Cell Therapy) receives positive CHMP opinion for treatment of blood cancer patients without access to suitable donor cells

Business Wire logo

BeiGene Advances Leadership in CLL at ASH 2024 with New Data From Its Hematology Franchise Including BRUKINSA® and Novel Pipeline Assets

Miltenyi Biomedicine presents primary analysis of the pivotal DALY 2-EU trial for second-line relapsed/refractory large B-cell lymphoma at the 67th American Society of Hematology (ASH) Annual Meeting